Dr E Neil Lewis, Chief Technology Officer at Malvern Instruments, leads the company’s Bioscience Development Initiative (BDI), which was established to work in tandem with the biotechnology and biopharmaceutical industries to rapidly identify, deliver and evaluate the new analytical technologies they need, in line with the rising interest in this field.
During a recent interview with Pharmaceutical Manufacturing Magazine, which is available to view online here, Neil talked about what is driving the demand for new analytical techniques in biopharmaceutical development, and how Malvern Instruments is addressing these challenges. Our Bioscience Development Initiative was established to encourage industry players to partner and share with us their challenges, to provide a vehicle for us to identify and target emerging technologies and to provide fast-moving, agile technology development.
Malvern Instruments offers a range of complementary technologies for the measurement of protein aggregation, including the recently introduced Archimedes, which uses Resonant Mass Measurement (RMM) technology to detect, in some cases speciate, and more importantly, count particles in the size range 50 nm – 5 µm. Other established solutions include the Viscotek range of Size Exclusion Chromatography (SEC), which are described in this article from Chromatography Today that discusses how multi-detector SEC can be used for the analysis of proteins, and the Zetasizer Dynamic Light Scattering (DLS) instruments.
For more information about protein aggregation, and examples of other applications in this sector, click here.
The work at Malvern’s BDI continues, and we encourage you to keep an eye out for the exciting new products that are currently being developed for release this year. For example, a new product that utilises microviscosity measurement technology for the automated screening of extremely small volume samples and formulations will be launching very soon. This instrument will enable potential issues with formulation viscosity to be identified at a very early stage in development. Problem candidates can therefore be excluded prior to major development investment, and the “fail early, fail cheap” mantra followed. Please watch this space for upcoming launch announcements!